In the eastern reaches of the Democratic Republic of Congo, a strain of Ebola called Bundibugyo is moving through a population already fractured by war, testing the limits of what public health can accomplish when its most basic tools — isolation, tracing, quarantine — are nearly impossible to deploy. The virus is not the familiar Zaire strain the world has learned to recognize, and that difference cost precious weeks of early detection. No licensed vaccine exists for this strain, and the candidates in development are months from human trials, leaving the oldest methods of containment as the o
Expert: Bundibugyo Ebola strain spreading in DRC conflict zone, vaccines months away
The Bundibugyo Ebola outbreak in DRC has caused multiple deaths and infections, with spread complicated by ongoing conflict forcing population displacement.
The virus keeps moving because authorities were looking for the wrong thing
Mark
Why did it take so long to realize this was Bundibugyo and not Zaire?
Mimi
Because when you're looking for one thing, you don't see another. Zaire is what everyone knows. The tests were calibrated for Zaire. By the time someone realized the virus was different, it had already spread.
Mark
So the diagnostic test itself was the problem?
Mimi
Partly. But also the assumption. In an outbreak, those first hours matter enormously. If you're testing for the wrong pathogen, you're not finding cases. You're not isolating people. The virus keeps moving.
Mark
Gandhi mentions the US withdrawal from the WHO. How directly does that affect what's happening in the DRC right now?
Mimi
It means there are fewer resources, fewer people on the ground, less coordination. The US used to be the backbone of rapid response. That capacity doesn't disappear overnight, but it's degraded. In a conflict zone where everything is already fragile, that loss is felt immediately.
Mark
Seven to nine months for a vaccine trial to even begin—that seems like a long time when cases are rising now.
Mimi
It is. That's why the old tools matter so much right now. Isolation, contact tracing, quarantine. They're not glamorous, but they work if you can actually do them. The vaccine is the long-term answer. The present answer is finding people and keeping them apart.
Mark
Is Gandhi saying this won't become a pandemic?
Mimi
She's saying the biology makes it unlikely. Ebola doesn't spread through air. It doesn't spread from asymptomatic people. That's its weakness. But that only matters if you can actually isolate the sick. In a conflict zone, that's the real question.
Mark
What does she think needs to happen?
Mimi
Health authorities that function. US investment back into global health infrastructure. Vigilance. And a vaccine that works. All of those things at once.
El Pulso
- The wrong strain was expected, the wrong tests were deployed, and by the time the WHO declared an emergency on May 17, Bundibugyo had already moved through communities undetected for critical weeks.
- Armed conflict is dismantling the basic architecture of outbreak response — people are crossing borders to flee violence, making contact tracing and quarantine nearly impossible to enforce.
- The withdrawal of the United States from the WHO and the collapse of USAID have removed a major pillar of global disease infrastructure at precisely the moment it is needed most.
- A spike in reported cases may signal progress rather than collapse — expanded testing is finding infections that can now be isolated before they spread further.
- The rVSV vaccine candidate is seven to nine months from trials, mRNA options are further behind still, and the existing Zaire vaccine has been deemed unsuitable, leaving the world without a biological shield.
- Ebola's transmission biology — requiring direct contact with body fluids, not airborne spread — remains the outbreak's natural limit, but only if containment holds.
In the eastern reaches of the Democratic Republic of Congo, a strain of Ebola called Bundibugyo is moving through a population already fractured by war, testing the limits of what public health can accomplish when its most basic tools — isolation, tracing, quarantine — are nearly impossible to deploy. The virus is not the familiar Zaire strain the world has learned to recognize, and that difference cost precious weeks of early detection. No licensed vaccine exists for this strain, and the candidates in development are months from human trials, leaving the oldest methods of containment as the only ones available. The risk of global spread remains low by the nature of the virus itself, but low is not zero, and the margin depends entirely on resources, attention, and the willingness of the world to remain present.
Monica Gandhi, an infectious disease specialist, has been explaining what makes this Ebola outbreak in the Democratic Republic of Congo different — and more difficult — than those the world has faced before.
The virus is Bundibugyo, a distinct member of the Ebola family with no licensed vaccine and no proven treatment. Because health authorities initially expected the more familiar Zaire strain, they deployed the wrong diagnostic tests. By the time the WHO declared a public health emergency on May 17, the virus had already spread through communities unchecked. The delay was not negligence so much as the cost of encountering something unexpected.
Containment is further complicated by the DRC's ongoing armed conflict. People are fleeing violence across borders, making the basic tools of outbreak response — isolate, trace, quarantine — extraordinarily difficult to use. Gandhi also notes that the U.S. withdrawal from the WHO and the dismantling of USAID have hollowed out the global infrastructure that once made coordinated response possible. That absence is being felt in real time.
A recent rise in case numbers may carry a measure of hope: expanded surveillance is finding infections that can now be isolated before they spread further. But without a vaccine, the only tools available are the oldest ones.
The WHO considered whether the existing Zaire vaccine might offer protection against Bundibugyo — the consensus was no. An rVSV-based candidate from the International AIDS Vaccine Initiative is in development but won't reach human trials for seven to nine months. mRNA candidates are further behind still.
Gandhi is measured about the risk of global spread: it is low. Ebola does not travel through the air, and it does not spread from people who are not yet symptomatic. Its biology is its own brake. But that brake only holds if contact tracing functions, if isolation is enforced, and if the world sustains its attention and resources long enough for a vaccine to cross the finish line. Until then, the oldest public health methods must be enough — and whether they are depends on conditions that remain deeply uncertain.
Monica Gandhi, an infectious disease specialist, sat down to explain what makes the current Ebola outbreak in the Democratic Republic of Congo different from previous ones—and why the world is scrambling to contain it.
The virus circulating now is Bundibugyo, a distinct member of the Ebola family that has no licensed vaccine and no proven treatment. This matters enormously. Most Ebola outbreaks in recent memory have been caused by the Zaire strain, which devastated West Africa between 2014 and 2016 in what remains the largest Ebola epidemic on record. Because health authorities initially expected Zaire, they were looking for the wrong thing. The diagnostic tests that would have caught Bundibugyo early were not deployed. By the time the World Health Organization declared a public health emergency on May 17, the virus had already moved through the population unchecked.
The outbreak is spreading in conditions that make containment extraordinarily difficult. The DRC is in the grip of armed conflict. People are fleeing violence, moving across borders, ignoring health directives. In a stable setting, stopping Ebola is straightforward: isolate the sick, trace their contacts, quarantine anyone exposed. In a war zone, those basic tools become nearly impossible to use. Gandhi points to another complication: the withdrawal of the United States from the WHO and the collapse of USAID have gutted the infrastructure that once made America a major force in global disease response. That absence is being felt now.
The rapid climb in case numbers over recent days could reflect something more hopeful than it appears on the surface. More diagnostic testing and active surveillance mean more cases are being found—which is good, because once a case is identified, the people who encountered that person can be quarantined before they spread it further. But the underlying reality remains: without a vaccine, the only weapons available are the old ones.
The race for a vaccine began the moment Bundibugyo was confirmed. The WHO considered whether Erbevo, the existing vaccine against Zaire, might work against this new strain. The consensus was no—not outside of carefully controlled research settings. Other candidates are in development. The International AIDS Vaccine Initiative is working on an rVSV-based vaccine using a viral vector approach, but it will not be ready for human trials for seven to nine months. Additional candidates using different viral vectors and mRNA technology are also in the pipeline, though they are further behind.
Gandhi is clear-eyed about the risk of global spread: it is low. Ebola does not travel through the air. It does not spread from people who have no symptoms yet. It moves only through direct contact with the blood and body fluids of someone who is sick or who has died. That biological fact is the outbreak's natural brake. If contact tracing works, if isolation is enforced, if quarantine holds, the virus will burn itself out. It will not become a pandemic.
But that if is enormous. It requires functioning health authorities on the ground. It requires the United States to reinvest in the WHO. It requires sustained attention and resources for as long as the outbreak lasts. And it requires that somewhere in the next months, a vaccine candidate crosses the finish line and proves itself safe and effective. Until then, the DRC and the world are holding their breath, hoping that the oldest public health tools—finding the sick, isolating them, protecting those around them—will be enough.
Citas Notables
Without any vaccines or treatment, the only way to contain the virus is isolation of someone who is sick, contact tracing, and quarantine of exposed contacts— Monica Gandhi, infectious disease expert
Ebola is spread by close contact with body fluids of an infected person, not by respiratory droplets or from asymptomatic people, so containment without global spread is feasible with effective isolation and quarantine— Monica Gandhi
Quieres la nota completa?
Lee el original en Medical News Today ↗
Health & Medicine